Viaplana E - Search Results

1

Taking a Promising Vaccine Candidate Further: Efficacy of ASFV-G-ΔMGF after Intramuscular Vaccination of Domestic Pigs and Oral Vaccination of Wild Boar.

Deutschmann P, Carrau T, Sehl-Ewert J, Forth JH, Viaplana E, Mancera JC, Urniza A, Beer M, Blome S. Deutschmann P, et al. Among authors: viaplana e. Pathogens. 2022 Aug 31;11(9):996. doi: 10.3390/pathogens11090996. Pathogens. 2022. PMID: 36145428 Free PMC article.

2

Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.

Alberca B, Bachanek-Bankowska K, Cabana M, Calvo-Pinilla E, Viaplana E, Frost L, Gubbins S, Urniza A, Mertens P, Castillo-Olivares J. Alberca B, et al. Among authors: viaplana e. Vaccine. 2014 Jun 17;32(29):3670-4. doi: 10.1016/j.vaccine.2014.04.036. Epub 2014 May 14. Vaccine. 2014. PMID: 24837765 Free PMC article.

3

In vitro and in vivo characterization of an infectious clone of a European strain of porcine circovirus type 2.

Roca M, Balasch M, Segalés J, Calsamiglia M, Viaplana E, Urniza A, Hattermann K, Mankertz A, Plana-Durán J, Domingo M. Roca M, et al. Among authors: viaplana e. J Gen Virol. 2004 May;85(Pt 5):1259-1266. doi: 10.1099/vir.0.79836-0. J Gen Virol. 2004. PMID: 15105543

4

Antigenicity of VP60 structural protein of rabbit haemorrhagic disease virus.

Viaplana E, Plana J, Villaverde A. Viaplana E, et al. Arch Virol. 1997;142(9):1843-8. doi: 10.1007/s007050050201. Arch Virol. 1997. PMID: 9672641

5

A recombinant foot-and-mouth disease virus antigen inhibits DNA replication and triggers the SOS response in Escherichia coli.

Benito A, Viaplana E, Corchero JL, Carbonell X, Villaverde A. Benito A, et al. Among authors: viaplana e. FEMS Microbiol Lett. 1995 Jun 15;129(2-3):157-62. doi: 10.1111/j.1574-6968.1995.tb07573.x. FEMS Microbiol Lett. 1995. PMID: 7607396

6

Polylinker-encoded peptides can confer toxicity to recombinant proteins produced in Escherichia coli.

Viaplana E, Villaverde A. Viaplana E, et al. Biotechnol Prog. 1996 Sep-Oct;12(5):723-7. doi: 10.1021/bp9600593. Biotechnol Prog. 1996. PMID: 8879160

7

Reversible activation of a cryptic cleavage site within E. coli beta-galactosidase in beta-galactosidase fusion proteins.

Viaplana E, Feliu JX, Corchero JL, Villaverde A. Viaplana E, et al. Biochim Biophys Acta. 1997 Dec 5;1343(2):221-6. doi: 10.1016/s0167-4838(97)00114-3. Biochim Biophys Acta. 1997. PMID: 9434112

8

The position of the heterologous domain can influence the solubility and proteolysis of beta-galactosidase fusion proteins in E. coli.

Corchero JL, Viaplana E, Benito A, Villaverde A. Corchero JL, et al. Among authors: viaplana e. J Biotechnol. 1996 Jul 31;48(3):191-200. doi: 10.1016/0168-1656(96)01508-8. J Biotechnol. 1996. PMID: 8861998

9

The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response in Escherichia coli.

Arís A, Corchero JL, Benito A, Carbonell X, Viaplana E, Villaverde A. Arís A, et al. Among authors: viaplana e. Biotechnol Bioeng. 1998 Dec 5;60(5):551-9. doi: 10.1002/(sici)1097-0290(19981205)60:5<551::aid-bit5>3.0.co;2-m. Biotechnol Bioeng. 1998. PMID: 10099463

10

The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response in escherichia coli.

Aris A, Corchero JL, Benito A, Carbonell X, Viaplana E, Villaverde A. Aris A, et al. Among authors: viaplana e. Biotechnol Bioeng. 1999 Jul 5;64(1):127. doi: 10.1002/(sici)1097-0290(19990705)64:1<127::aid-bit14>3.0.co;2-0. Biotechnol Bioeng. 1999. PMID: 10397847 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page